This document provides information on renal cell carcinoma (RCC), including epidemiology, risk factors, histologic subtypes, staging, clinical presentation, investigations, and management. RCC accounts for 2-3% of adult cancers. Clear cell RCC is the most common subtype. Presentation is often nonspecific, though flank pain, hematuria, and abdominal mass may occur. Imaging like CT and MRI are used to stage and characterize lesions. Treatment involves surgery (radical or partial nephrectomy) for localized disease. Up to 30% of patients experience relapse post-surgery.
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Siewhong Ho
Dr Ho lectured at the Asian Oncology Summit 2013 in Bangkok on the surgical opinion on management of renal cell carcinoma. He presented to a varied audience of medical oncologist, radiation oncologist, urologists, researchers, para clinical staff and nurses. The most interesting aspect of the lecture was on the role of urologists in management of Stage 4 kidney cancer in the era of 'targeted therapy'. The role of cytoreductive nephrectomy was reviewed potential future developments in this area was discussed
Testicular tumors are rare.
1 – 2 % of all malignant tumors.
Most common malignancy in men in the 15 to 35 year age group.
Benign lesions represent a greater percentage of cases in children than in adults.
Most curable solid neoplasm
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Siewhong Ho
Dr Ho lectured at the Asian Oncology Summit 2013 in Bangkok on the surgical opinion on management of renal cell carcinoma. He presented to a varied audience of medical oncologist, radiation oncologist, urologists, researchers, para clinical staff and nurses. The most interesting aspect of the lecture was on the role of urologists in management of Stage 4 kidney cancer in the era of 'targeted therapy'. The role of cytoreductive nephrectomy was reviewed potential future developments in this area was discussed
Testicular tumors are rare.
1 – 2 % of all malignant tumors.
Most common malignancy in men in the 15 to 35 year age group.
Benign lesions represent a greater percentage of cases in children than in adults.
Most curable solid neoplasm
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
2. • 2% to 3% of all adult malignant neoplasms
• Most lethal of the common urologic cancers.
• 12 new cases per 100000 population
• male-to-female predominance of 3 : 2
• sixth and seventh decades of life
3. • Majority sporadic- 2%to 3 % familial
• Incidence is increasing 3-4% per year
• Mortality rates are also increasing
• RCC in childhood is uncommon
• RCC as common as Wilms tumour during second decade of life
• Chidrens and young adults may respond to surgical treatment
better than elderly
4. India
• Incidence: 15-22/100,000/Yr, 2% of all malignant tumors,
• In India : Males: 1.2/100,000, Females : 0.5/ 100,000
• Indians living in western countries have higher incidence
• M:F = 2:1
• Age peak: 50 to 70 years
• India : mean age – 52 years
5. Incidence of Urologic Malignancies in India: Age
adjusted incidence rate (Per 100,000 populations)
11. • RCC in VHL
–Early age of onset
–Bilateral
–Multifocal involvement
–Most common cause of mortality
–Clear cell carcinoma
–Hypervascular
12.
13. Hereditary papillary RCC (HPRCC)
• Type 1 papillary RCC
• Activation of proto oncogene
• C-MET protooncogene at 7q31
• Receptor thyrosine kinase for hepatocyte growth factor
• Autosomal dominant mode of transmission
• Trisomy of chromosome 7 was described as hallmark features
of papillary renal tumours
14. Type 2 heridetary leiomyomatosis and renal cell carcinoma
• Renal tumours are solitary, unilateral and most aggressive
• Collecting duct RCC are also common
• Large, prominent eosinophilic nuclei and nucleoli with perinuclear clearing
• Locus mapped in region of 1q42-44, site of fumarate hydratase gene
• Tumour suppressor gene
• Autosomal dominant inheritance
• RCC lower than cutaneous and uterine manifestations
• 20% of patient develop RCC
• Fumerate accumulation stabilize HIF1
15. XP11.2 translocations of RCC
• Tumours detected in young children and adolescent
• Tranlocations involving Xp11.2 and 1q21.2
• Associated with papillary cancers
• Fusion protein PRCC-TFE3
• Strong transcription activator of MET
16. Brit-Hogg-Dube syndrome
• Renal tumours are chromophobe RCC, oncocytoma, hybride or
transitional cell carcinomas
• Other features are cutaneous fibrofolliculomas, lung cyst,
sponataneous pneumothorax
• Penetrance of RCC 20-40%
• Bilateral and multifocal
• Average age of presentation 50yrs
• Mapped on 17p12, folliculine
• Folliculin may interface with mTOR pathway
• Autosomal dominant pattern
17. Tuberous sclerosis complex
• Predominant renal manifestation is angiomyolipoma, RCC 2-3%
• Othe manifestations are facial angiofibroma,
lymphangiomatosis of lung, neurological manifestations
• TSC1- hemartin, TSC2 – tuberin
• Both negatively egulate mTOT signaling
19. • Immunobiology and immune tolerance
– Tumour associated antigens
• Carbonic anhydrase IX
• B7 family surface glycoprotein
• Spontaneous regression 0.3 to 7%
20. Pathology
• All RCC are by definition adenocarcinomas, derived from
renal tubular epithelial cells
• Gross – round or ovoid shape, circumscribed by
pseudocapsule
• Cystic degeneration 10-25% (associated with better
prognosis)
• Calcification can be stippled or plaque like – 10-20%
• Predilection for involvement of venous system 10%RCC
21. • Clear cell renal carcinoma
– 70-80% of all RCC
– Tumour typically yellow, highly vascular
– Clear cell, granular cell, or mixed
– Clear cell – round or polygonal with abundant cytoplasm
containing glycogen, cholesterol, cholesterol esters, and
phospholipids,
– All of which are readily extracted by the solvents used in routine
histologic preparations, contributing to the clear appearance of
the tumor cells
22. – Granular cells -- eosinophilic cytoplasm and abundant mitochondria,
can predominate.
– Two to 5 percent of clear cell RCC demonstrate sarcomatoid features
– Clear cell RCC is more likely to exhibit venous tumor extension than
any other subtype of RCC
– Chromosome 3 alterations and VHL mutations are common in clear
cell RCC, and mutation or inactivation of this gene has been found in
a majority of sporadic cases
23.
24. • Papillary Renal Cell Carcinoma
– Second most common histologic subtype
– It represents 10% to 15% of all RCCs
– More commonly found in patients with end-stage renal failure and
acquired renal cystic disease
– Basophilic or eosinophilic cells arranged in papillary or tubular
configuration
25. – More than 50% or 75% of the tumor had to exhibit such architectural
features to qualify as a papillary RCC
– Multicentricity, which approaches 40% in many series
– Type 1 papillary RCC, the more common form, consists of basophilic
cells with scant cytoplasm
– Type 2 papillary RCC include potentially more aggressive variants with
eosinophilic cells and abundant granular cytoplasm
26.
27. • Chromophobe Renal Cell Carcinoma
– Derived from the cortical portion of the collecting duct
– It represents 3% to 5% of all RCCs
– The tumor cells typically exhibit a relatively transparent cytoplasm
with a fine reticular pattern that has been described as a “plant
cell” appearance
– Perinuclear clearing or “halo” is typically found and electron
microscopic findings
28. – Microvesicles characteristically stain positive for Hale colloidal iron,
indicating the presence of a mucopolysaccharide unique to
chromophobe RCC
– Better prognosis for localized chromophobe RCC than for clear cell
RCC but a poor outcome in the subset of patients with sarcomatoid
features or metastatic disease
29.
30. • Collecting Duct Carcinoma
– Less than 1% of all RCCs
– Occurred in younger patients, often in the third, fourth, or fifth
decades of life
– up to 50% have metastatic disease at the time of detection
– Ulex europaeus agglutinin 1 reactivity and positivity for E-cadherin
and c-KIT
– On microscopic examination, these tumors consist of an admixture of
dilated tubules and papillary structures typically lined by a single
layer of cuboidal cells, often creating a cobblestone appearance
31. • Renal Medullary Carcinoma
– Exclusively in association with the sickle cell trait
– Arise from the calyceal epithelium near the renal papillae
• Sarcomatoid Differentiation
– Sarcomatoid differentiation is characterized by spindle cell
histology, positive staining for vimentin, infiltrative growth
pattern, aggressive local and metastatic behavior, and poor
prognosis
– Found in 1% to 5% of RCCs, most commonly in association with
clear cell RCC or chromophobe RCC
32. • Unclassified Renal Cell Carcinoma
– Most are poorly differentiated and are associated with a highly
aggressive biologic behavior and a particularly poor prognosis
33. Clinical Presentation
• Kidney within the retroperitoneum, many renal masses remain
asymptomatic and nonpalpable until they are advanced.
• With the more pervasive use of noninvasive imaging for the
evaluation of a variety of nonspecific symptom complexes, more
than 50% of RCCs are now detected incidentally
• The classic triad of flank pain, gross hematuria, and palpable
abdominal mass is now rarely found - too late triad 10%
• In advanced stage: hematuria 60%, flank pain-40%, palpable
abdominal mass- 45%,
• Weight loss 35%, Anemia- 20%, varicocele, edema of leg (due to
invasion of renal vein or IVC)
34.
35.
36. • METASTATIC SPREAD
• 30% of cases have distant
metastasis at diagnosis
• Tumor < 3cm in diameter-
usually without metastasis
• Hematogenous metastasis -
Lung, liver, bone, CNS
• Lymphatic : to pelvic and para-
aortic lymph nodes
• Local : to regional lymph nodes:
para-aortic, paracaval, renal
hilar lymph nodes
37. • Stauffer syndrome
– Non metastatic hepatic dysfunction
– 3-20% of cases
– Almost all patients with Stauffer syndrome have an elevated serum alkaline
phosphatase level, 67% have elevated prothrombin time or
hypoalbuminemia, and 20% to 30% have elevated serum bilirubin or
transaminase levels
– Other common findings include thrombocytopenia and neutropenia, and
typical symptoms include fever and weight loss, many patients are found to
harbor discrete regions of hepatic necrosis .
– Biopsy - demonstrates nonspecific hepatitis associated with a prominent
lymphocytic infiltrate
– Elevated serum levels of IL-6 - this and other cytokines may play a pathogenic
role
– Hepatic function normalizes after nephrectomy in 60% to 70% of cases.
– Persistence or recurrence of hepatic dysfunction is almost always indicative
of the presence of viable tumor and thus represents a poor prognostic
finding
39. Investigations
• Intravenous pyelography
– Lack of sensitivity and specificity of intravenous pyelography for the
detection of parenchyma tumors is well documented
– Miss small anterior or posterior lesions that do not distort the
collecting system or the contour of the kidney.
– Features suggestive of malignancy
• Calcification within the mass
• Increased tissue density
• Irregularity of the margin and
• Distortion of the collecting system
40. • Ultrasonography
– Performed because it is noninvasive, accurate, and relatively
inexpensive
– Reliable for differentiation of solid tissue from fluid and can
establish the diagnosis of a simple renal cyst
– Criteria for simple cysts have been defined and include a
• Smooth cyst wall, a
• Round or oval shape without internal echoes, and
• Through-transmission with strong acoustic shadows posteriorly.
– If these criteria are met, observation is sufficient in an
asymptomatic patient
– Renal mass that is not clearly a simple cyst by strict ultrasound
criteria should be evaluated further with computed tomography
(CT)
41. • CT scan
– Any renal mass that enhances with intravenous administration of contrast
material on CT by more than 15 Hounsfield units (HU) should be
considered an RCC until proved otherwise (Hartman et al, 2004).
– Solid masses that also have substantial areas of negative CT attenuation
numbers (below −20 HU) indicative of fat are diagnostic of AMLs
– 10% to 20% of solid renal masses CT findings are indeterminate, and
additional testing or surgical exploration is needed to establish a definitive
diagnosis
42. • Magnetic resonance imaging (MRI)
• Renal arteriography has a limited role in the diagnostic
evaluation of renal masses and is primarily reserved for
patients with concomitant renal artery disease
• Renal mass biopsy is now being revisited for the evaluation
of renal masses
– False-negative rate of renal mass biopsy was thought to be 18%
– Overall accuracy is greater than 80%.
– Assessment of tumor grade and histologic type, which reflects tumor
aggressiveness, is also accurate in the majority of cases
– The risks of clinically significant perinephric bleeding and
pneumothorax also appear to be low (<1%), and needle tract seeding is
exceedingly rare when centrally located, infiltrative renal masses are
excluded.
43. • Renal mass biopsy is now being considered more frequently,
particularly in
– Younger, healthy patients who are unwilling to accept the uncertainty
associated with renal mass biopsy are still typically managed
primarily based on radiographic and clinical considerations.
– Suspicion of renal abscess
– When RCC must be differentiated from metastatic malignant disease
– Renal lymphoma
53. • Prognostic Factors – MSKCC Scoring System
• Poor-prognosis patients are defined as those having ≥ 3 more
factors: these are predictors of short survival:
• Serum LDH > 1.5 times the upper limit of normal
• Hemoglobin (g/dl) : < lower limit of normal
• Corrected serum Calcium > 10 mg/dL (2.5 mmol/L)
• Interval less than a year from original diagnosis to start of systemic
therapy
• Karnofsky Performance Score ≤ 70
• ≥ 2 sites of organ metastasis
54.
55.
56. Management of localized RCC
SURGERY -
•Radical nephrectomy
•Nephron sparing partial nephrectomy
OTHER MODALITIES
•Radiotherapy
•Chemotherapy
•Targeted molecular therapy
57.
58. • it includes a systematic approach with careful mobilization of
Gerota’s fascia and early vascular control.
•
• For left-sided exposure, the lienorenal ligament is incised to
mobilize the spleen cephalad.
• On the right side, the hepatic flexure of the colon is mobilized.
• The plane between the mesentery of the colon and Gerota’s fascia
is then developed using a combination of sharp and blunt
dissection.
• On the right side, the vena cava is exposed by Kocherizing the
duodenum.
• Using blunt dissection, the retroperitoneal fat overlying the renal
vessels is separated, exposing the renal hilum.
61. Thermal abalition therapy
• Cryo /RFA : altrnative to NSS
• done by lap / percuteniously
• local recurence is high
• Ideal candites : advance age with significant co morbidity
• local recurence after previous nss
• multiple lesion in wich nss is combersome
62. Locally advance disease
• Stages II and III. Locally advanced tumors are managed with
radical nephrectomy, which can require resection of adjacent
organs, and with tumor thrombectomy from the renal vein and
possibly the inferior vena cava.
• Between 40% and 60% of patients can be cured with such an
aggressive surgical approach.
63.
64. • After surgical excision, up to 30% of patients with localized tumors
experience relapse.
• The lung is the most common site of distant recurrence, seen in
50% to 60% of patients.
• The median time to relapse after surgery is approximately 2 years,
with most relapses occurring within 5 years.
• Interferon alpha and high-dose interleukin-2 (IL-2) have been
tested as adjuvant treatments following resection of stage 1-2
kidney cancer. However, no benefit has been seen in randomized
trials.
65. • (NCCN) Kidney Cancer Panel has recommended that patients
be seen every 6 months for the first 2 years after surgery and
annually thereafter.
• Each visit should include a history, physical examination, and
comprehensive metabolic panel (eg, blood urea nitrogen,
serum creatinine, calcium levels, LDH, and liver function tests).
Abdominal and chest imaging studies should be done
approximately 2 to 6 months after surgery and as clinically
indicated thereafter.
66. • Overall invoveloment of venous system in rcc is 4% to 10%
• Clinical suspicion in case of rcc with lower extremity edema ,
isolated rt sided varicocele .
• Staging of ivc thrombus
• level 1 ; ADJUCENT to renal ostium of renal vein
• Level 2 extending up to lower aspect of liver
• Level 3 intrahepatic portion of ivc
• Level 4 aboveb diaphragm
67.
68. • Stage IV. Cytoreductive nephrectomy before systemic therapy
is recommended in patients with a surgically resectable
primary tumor.
• Metastasectomy should be considered in patients with
favorable features such as a solitary metastasis or a long
interval between initial diagnosis and the development of
metastatic disease.
• In these patients, the 5-year disease-free survival rate can be
as high as 30%.
69.
70. • Systemic therapy is recommended for patients with residual
metastatic disease,
• though patients with low-volume indolent metastases may
initially undergo a period of observation.
• Several systemic agents exist today that are non-curative and
therefore require long-term sequential therapy with multiple
agents and management of toxicity.
71. • Immunotherapy
• IL-2. In selected patients with relapsed or medically unresectable stage IV
clear-cell RCC.
• high-dose IL-2 can be considered as a first-line treatment option.
• Although no demonstrable OS benefit has been seen, durable complete
remissions occur in 7% to 8% of patients.
• Thus, despite the associated toxicity of capillary leak syndrome, IL-2
remains a viable treatment option reserved for patients with good
performance status and acceptable comorbid disorders.
• Unfortunately, there are no predictive biomarkers upon which to base the
selection of patients for treatment with high-dose IL-2.
72. • Bevacizumab plus interferon alpha:
• This combination has been associated with a 31% objective
response rate with a median PFS of 10.2 months.